INOGRAFT BIOTHERAPEUTICS
Live / Allowed — Third extension granted (statement of use) (as of 23 Jun 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 13 May 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98547760
- Mark type
- Word mark
- Filed
- 13 May 2024
- Published for opposition
- 24 Dec 2024
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 001 — Chemicals: Stem cells for research purposes; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; decoy receptors being biochemicals for in vitro scientific or research use
- Class 005 — Pharmaceuticals: Stem cell-derived drug therapies being biological preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cell-derived therapeutic pharmaceutical preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cells for therapeutic treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases for medical purposes; pharmaceutical preparations as CD47 antagonists, integrin-associated proteins (IAP), and CD47 glycoproteins for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; monoclonal antibodies for medical purposes; monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants for medical purposes
- Class 042 — Scientific and technological services: Research and development services relating to bone marrow, stem cell, and organ transplantation; research and development in the field of stem cell therapies; research and development relating to bone marrow, stem-cell, and organ transplantation; research and development relating to pharmaceutical preparations as CD47 antagonists, integrin-associated proteins, and CD47 glycoproteins; research and development services in the field of antibodies; research and development relating to using monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants
Owner
- Inograft Biotherapeutics, Inc., Palo Alto, CA, US
- Inograft Biotherapeutics, Inc., Palo Alto, CA, US
Prosecution history
- 23 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Jun 2026 — SOU EXTENSION 3 GRANTED
- 22 Jun 2026 — SOU EXTENSION 3 FILED
- 22 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 14 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Feb 2026 — SOU EXTENSION 2 GRANTED
- 04 Feb 2026 — SOU EXTENSION 2 FILED
- 04 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jul 2025 — SOU EXTENSION 1 GRANTED
- 09 Jul 2025 — SOU EXTENSION 1 FILED
- 09 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 24 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Dec 2024 — PUBLISHED FOR OPPOSITION